<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39407979</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>04</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Process-Specific Blood Biomarkers and Outcomes in COVID-19 Versus Non-COVID-19 ARDS (APEL-COVID Study): A Prospective, Observational Cohort Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5919</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13195919</ELocationID><Abstract><AbstractText><b>Background:</b> Severe acute respiratory syndrome (SARS) and acute respiratory distress syndrome (ARDS) are often considered separate clinico-radiological entities. Whether these conditions also present a single process-specific systemic biomolecular phenotype and how this relates to patient outcomes remains unknown. A prospective cohort study was conducted, including adult patients admitted to the ICU and general floors for COVID-19-related (COVID+) or non-COVID-19-related (COVID-) acute respiratory failure during the main phase of the pandemic. The primary objective was to study blood biomarkers and outcomes among different groups and severity subsets. <b>Results:</b> A total of 132 patients were included, as follows: 67 COVID+, 54 COVID- (with 11 matched control subjects for biomarker reference), and 58 of these patients allowed for further pre- and post-analysis. The baseline apelin (APL) levels were higher in COVID+ patients (<i>p</i> &lt; 0.0001 vs. COVID- patients) and in SARS COVID+ patients (<i>p</i> ≤ 0.02 vs. ARDS), while the IL-6 levels were higher in ARDS COVID- patients (<i>p</i> ≤ 0.0001 vs. SARS). Multivariable logistic regression analyses with cohort biomarkers and outcome parameters revealed the following: (i) log-transformed neprilysin (NEP) activity was significantly higher in COVID+ patients (1.11 [95% CI: 0.4-1.9] vs. 0.37 [95% CI: 0.1-0.8], fold change (FC): 1.43 [95% CI: 1.04-1.97], <i>p</i> = 0.029) and in SARS patients (FC: 1.65 [95% CI: 1.05-2.6], <i>p</i> = 0.032 vs. non-SARS COVID+ patients, and 1.73 [95% CI: 1.19-2.5], <i>p</i> = 0.005 vs. ARDS COVID- patients) and (ii) higher lysyl oxidase (LOX) activity and APL levels were respectively associated with death and a shorter length of hospital stay in SARS COVID+ patients (Odds Ratios (OR): 1.01 [1.00-1.02], <i>p</i> = 0.05, and OR: -0.007 [-0.013-0.0001], <i>p</i> = 0.048). <b>Conclusion:</b> Process-specific blood biomarkers exhibited distinct profiles between COVID+ and COVID- patients, and across stages of severity. NEP and LOX activities, as well as APL levels, are particularly linked to COVID+ patients and their outcomes (ClinicalTrials.gov Identifier: NCT04632732).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lesur</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-2938-4744</Identifier><AffiliationInfo><Affiliation>Centre de Recherche Clinique du CHU Sherbrooke (CRCHUS), Department of Intensive Care Medicine, Faculty of Medicine and Health Sciences, University of Sherbrooke, 3001 12th Avenue Nord, Sherbrooke, QC J1H 5N4, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Départements de Soins Intensifs et Service de Pneumologie, CHU Sherbrooke, 3001, 12th Avenue Nord, Sherbrooke QC J1H 5N4, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Médecine, CHU Sherbrooke, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segal</LastName><ForeName>Eric David</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Département de Médecine, CHU Sherbrooke, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rego</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre de Recherche Clinique du CHU Sherbrooke (CRCHUS), Department of Intensive Care Medicine, Faculty of Medicine and Health Sciences, University of Sherbrooke, 3001 12th Avenue Nord, Sherbrooke, QC J1H 5N4, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Départements de Soins Intensifs et Service de Pneumologie, CHU Sherbrooke, 3001, 12th Avenue Nord, Sherbrooke QC J1H 5N4, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Médecine, CHU Sherbrooke, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercat</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Département de Médecine Intensive-Réanimation, CHU Angers, 49000 Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asfar</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Département de Médecine Intensive-Réanimation, CHU Angers, 49000 Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chagnon</LastName><ForeName>Frédéric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre de Recherche Clinique du CHU Sherbrooke (CRCHUS), Department of Intensive Care Medicine, Faculty of Medicine and Health Sciences, University of Sherbrooke, 3001 12th Avenue Nord, Sherbrooke, QC J1H 5N4, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04632732</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>covid19 2020</GrantID><Agency>CRC-CHUS special covid19 funding</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE2</Keyword><Keyword MajorTopicYN="N">ARDS</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">LOX</Keyword><Keyword MajorTopicYN="N">NEP</Keyword><Keyword MajorTopicYN="N">SARS</Keyword><Keyword MajorTopicYN="N">apelins (APL)</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39407979</ArticleId><ArticleId IdType="pmc">PMC11477790</ArticleId><ArticleId IdType="doi">10.3390/jcm13195919</ArticleId><ArticleId IdType="pii">jcm13195919</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Azagew A.W., Beko Z.W., Ferede Y.M., Mekonnen H.S., Abate H.K., Mekonnen C.K. Global prevalence of COVID-19-induced acute respiratory distress syndrome: Systematic review and meta-analysis. Syst. Rev. 2023;12:212. doi: 10.1186/s13643-023-02377-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-023-02377-0</ArticleId><ArticleId IdType="pmc">PMC10644454</ArticleId><ArticleId IdType="pubmed">37957723</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Zangrillo A., Beretta L., Scandroglio A.M., Monti G., Fominskiy E., Colombo S., Morselli F., Belletti A., Silvani P., Crivellari M., et al. Characteristics treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. Crit. Care Resusc. 2020;22:200–211. doi: 10.1016/S1441-2772(23)00387-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1441-2772(23)00387-3</ArticleId><ArticleId IdType="pmc">PMC10692521</ArticleId><ArticleId IdType="pubmed">32900326</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G., Calfee C.S., Camporota L., Poole D., Amato M.B.P., Antonelli M., Arabi Y.M., Baroncelli F., Beitler J.R., Bellani G., et al. European Society of Intensive Care Medicine Taskforce on ARDS. ESICM guidelines on acute respiratory distress syndrome: Definition, phenotyping and respiratory support strategies. Intensive Care Med. 2023;49:727–759. doi: 10.1007/s00134-023-07050-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-023-07050-7</ArticleId><ArticleId IdType="pmc">PMC10354163</ArticleId><ArticleId IdType="pubmed">37326646</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattinoni L., Coppola S., Cressoni M., Busana M., Rossi S., Chiumello D. COVID-19 Does Not Lead to a “Typical” Acute Respiratory Distress Syndrome. Am. J. Respir. Crit. Care Med. 2020;201:1299–1300. doi: 10.1164/rccm.202003-0817LE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202003-0817LE</ArticleId><ArticleId IdType="pmc">PMC7233352</ArticleId><ArticleId IdType="pubmed">32228035</ArticleId></ArticleIdList></Reference><Reference><Citation>Toniati P., Piva S., Cattalini M., Garrafa E., Regola F., Castelli F., Franceschini F., Airò P., Bazzani C., Beindorf E.A., et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun. Rev. 2020;19:102568. doi: 10.1016/j.autrev.2020.102568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102568</ArticleId><ArticleId IdType="pmc">PMC7252115</ArticleId><ArticleId IdType="pubmed">32376398</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralinski L.E., Bankhead A., Jeng S., Menachery V.D., Proll S., Belisle S.E., Matzke M., Webb-Robertson B.J., Luna M.L., Shukla A.K., et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio. 2013;4:e00271-13. doi: 10.1128/mBio.00271-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00271-13</ArticleId><ArticleId IdType="pmc">PMC3747576</ArticleId><ArticleId IdType="pubmed">23919993</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold S., Gabrielli N.M., Vadász I. Novel concepts of acute lung injury and alveolar-capillary barrier dysfunction. Am. J. Physiol. Lung Cell Mol. Physiol. 2013;305:L665–L681. doi: 10.1152/ajplung.00232.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00232.2013</ArticleId><ArticleId IdType="pubmed">24039257</ArticleId></ArticleIdList></Reference><Reference><Citation>Joffre J., Rodriguez L., Matthay Z.A., Lloyd E., Fields A.T., Bainton R.J., Kurien P., Sil A., Calfee C.S., Woodruff P.G., et al. COVID-19 Multi-Phenotyping for Effective Therapies (COMET) Consortium; COVID-19 Associated Coagulopathy, Inflammation, and Thrombosis (Co-ACIT) Study Group. COVID-19-associated Lung Microvascular Endotheliopathy: A “From the Bench” Perspective. Am. J. Respir. Crit. Care Med. 2022;206:961–972. doi: 10.1164/rccm.202107-1774OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202107-1774OC</ArticleId><ArticleId IdType="pmc">PMC9801996</ArticleId><ArticleId IdType="pubmed">35649173</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., Rosas I.O., Singer M. Understanding post-COVID-19 interstitial lung disease (ILD): A new fibroinflammatory disease entity. Intensive Care Med. 2022;48:1803–1806. doi: 10.1007/s00134-022-06877-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-022-06877-w</ArticleId><ArticleId IdType="pmc">PMC9453725</ArticleId><ArticleId IdType="pubmed">36074167</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart I., Jacob J., George P.M., Molyneaux P.L., Porter J.C., Allen R.J., Aslani S., Baillie J.K., Barratt S.L., Beirne P., et al. Residual Lung Abnormalities after COVID-19 Hospitalization: Interim Analysis of the UKILD Post-COVID-19 Study. Am. J. Respir. Crit. Care Med. 2023;207:693–703. doi: 10.1164/rccm.202203-0564OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202203-0564OC</ArticleId><ArticleId IdType="pmc">PMC10037479</ArticleId><ArticleId IdType="pubmed">36457159</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya J., Matthay M.A. Regulation and repair of the alveolar-capillary barrier in acute lung injury. Annu. Rev. Physiol. 2013;75:593–615. doi: 10.1146/annurev-physiol-030212-183756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-physiol-030212-183756</ArticleId><ArticleId IdType="pubmed">23398155</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui L., Zhang X., An X., Li J., Zang K., Shang F., Zhang C., Zhang G. Higher serum procalcitonin and IL-6 levels predict worse diagnosis for acute respiratory distress syndrome patients with multiple organ dysfunction. Int. J. Clin. Exp. Pathol. 2017;10:7401–7407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6965210</ArticleId><ArticleId IdType="pubmed">31966582</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Shankar-Hari M., Vale C.L., Godolphin P.J., Fisher D., Higgins J.P.T., Spiga F., Savovic J., Tierney J., Baron G., et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021;2326:499–518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261689</ArticleId><ArticleId IdType="pubmed">34228774</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen G.L. Surfactant Protein D in Respiratory and Non-Respiratory Diseases. Front. Med. 2018;5:18. doi: 10.3389/fmed.2018.00018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2018.00018</ArticleId><ArticleId IdType="pmc">PMC5809447</ArticleId><ArticleId IdType="pubmed">29473039</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisner M.D., Parsons P., Matthay M.A., Ware L., Greene K. The Acute Respiratory Distress Syndrome Network. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax. 2003;58:983–988. doi: 10.1136/thorax.58.11.983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thorax.58.11.983</ArticleId><ArticleId IdType="pmc">PMC1746524</ArticleId><ArticleId IdType="pubmed">14586055</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene K.E., Jr., King T.E., Kuroki Y., Bucher-Bartelson B., Hunninghake G.W., Newman L.S., Nagae H., Mason R.J. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur. Respir. J. 2002;19:439–446. doi: 10.1183/09031936.02.00081102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.02.00081102</ArticleId><ArticleId IdType="pubmed">11936520</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall R.P., Simpson J.K., Lukey P.T. Strategies for biomarker discovery in fibrotic disease. Biochim. Biophys. Acta. 2013;1832:1079–1087. doi: 10.1016/j.bbadis.2013.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2013.01.018</ArticleId><ArticleId IdType="pubmed">23376113</ArticleId></ArticleIdList></Reference><Reference><Citation>Leeming D.J., Genovese F., Sand J.M.B., Rasmussen D.G.K., Christiansen C., Jenkins G., Maher T.M., Vestbo J., Karsdal M.A. Can biomarkers of extracellular matrix remodelling and wound healing be used to identify high risk patients infected with SARS-CoV-2? lessons learned from pulmonary fibrosis. Respir. Res. 2021;22:38. doi: 10.1186/s12931-020-01590-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01590-y</ArticleId><ArticleId IdType="pmc">PMC7863042</ArticleId><ArticleId IdType="pubmed">33546680</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien J.W., Richards T.J., Gibson K.F., Zhang Y., Lindell K.O., Shao L., Lyman S.K., Adamkewicz J.I., Smith V., Kaminski N., et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur. Respir. J. 2014;43:1430–1438. doi: 10.1183/09031936.00141013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00141013</ArticleId><ArticleId IdType="pubmed">24177001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesur O., Chagnon F., Lebel R., Lepage M. In Vivo Endomicroscopy of Lung Injury and Repair in ARDS: Potential Added Value to Current Imaging. J. Clin. Med. 2019;8:1197. doi: 10.3390/jcm8081197.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8081197</ArticleId><ArticleId IdType="pmc">PMC6723156</ArticleId><ArticleId IdType="pubmed">31405200</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsault E., Llorens-Cortes C., Iturrioz X., Chun H.J., Lesur O., Oudit G.Y., Auger-Messier M. The apelinergic system: A perspective on challenges and opportunities in cardiovascular and metabolic disorders. Ann. N Y Acad. Sci. 2019;1455:12–33. doi: 10.1111/nyas.14123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.14123</ArticleId><ArticleId IdType="pmc">PMC6834863</ArticleId><ArticleId IdType="pubmed">31236974</ArticleId></ArticleIdList></Reference><Reference><Citation>Coquerel D., Sainsily X., Dumont L., Sarret P., Marsault É., Auger-Messier M., Lesur O. The apelinergic system as an alternative to catecholamines in low-output septic shock. Crit. Care. 2018;22:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5774146</ArticleId><ArticleId IdType="pubmed">29347994</ArticleId></ArticleIdList></Reference><Reference><Citation>Berta J., Kenessey I., Dobos J., Tovari J., Klepetko W., Jan Ankersmit H., Hegedus B., Renyi-Vamos F., Varga J., Lorincz Z., et al. Apelin expression in human non-small cell lung cancer: Role in angiogenesis and prognosis. J. Thorac. Oncol. 2010;5:1120–1129. doi: 10.1097/JTO.0b013e3181e2c1ff.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JTO.0b013e3181e2c1ff</ArticleId><ArticleId IdType="pubmed">20581707</ArticleId></ArticleIdList></Reference><Reference><Citation>Godoy R.S., Cober N.D., Cook D.P., McCourt E., Deng Y., Wang L., Schlosser K., Rowe K., Stewart D.J. Single-cell transcriptomic atlas of lung microvascular regeneration after targeted endothelial cell ablation. eLife. 2023;12:e80900. doi: 10.7554/eLife.80900.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.80900</ArticleId><ArticleId IdType="pmc">PMC10181823</ArticleId><ArticleId IdType="pubmed">37078698</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Chen S., Zeng M., Lin D., Wang Y., Wen X., Xu C., Yang L., Fan X., Gong Y., et al. Apelin-13 Administration Protects Against LPS-Induced Acute Lung Injury by Inhibiting NF-κB Pathway and NLRP3 Inflammasome Activation. Cell Physiol. Biochem. 2018;49:1918–1932. doi: 10.1159/000493653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000493653</ArticleId><ArticleId IdType="pubmed">30235451</ArticleId></ArticleIdList></Reference><Reference><Citation>de Visser Y.P., Walther F.J., Laghmani E.H., van der Laarse A., Wagenaar G.T.M. Apelin Attenuates Hyperoxic Lung and Heart Injury in Neonatal Rats. Am. J. Respir. Crit. Care Med. 2010;182:1239–1250. doi: 10.1164/rccm.200909-1361OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200909-1361OC</ArticleId><ArticleId IdType="pmc">PMC3001263</ArticleId><ArticleId IdType="pubmed">20622042</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Li F., Su X., Li Y., Wang Y., Fang R., Guo Y., Jin T., Shan H., Zhao X., et al. Melatonin prevents lung injury by regulating apelin 13 to improve mitochondrial dysfunction. Exp. Mol. Med. 2019;51:1–12. doi: 10.1038/s12276-019-0273-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-019-0273-8</ArticleId><ArticleId IdType="pmc">PMC6802616</ArticleId><ArticleId IdType="pubmed">31273199</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao R., Wu Y., Yang Q., Chen L., Chen J., Wang B., Liu Z., Jin J., Li J., Wu G. The Interaction of Apelin and FGFR1 Ameliorated the Kidney Fibrosis through Suppression of TGFβ-Induced Endothelial-to-Mesenchymal Transition. Oxid. Med. Cell Longev. 2023;2023:5012474. doi: 10.1155/2023/5012474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2023/5012474</ArticleId><ArticleId IdType="pmc">PMC9922196</ArticleId><ArticleId IdType="pubmed">36785790</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., McKinnie S.M., Farhan M., Paul M., McDonald T., McLean B., Llorens-Cortes C., Hazra S., Murray A.G., Vederas J.C., et al. Angiotensin-Converting Enzyme 2 Metabolizes and Partially Inactivates Pyr-Apelin-13 and Apelin-17: Physiological Effects in the Cardiovascular System. Hypertension. 2016;68:365–377. doi: 10.1161/HYPERTENSIONAHA.115.06892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.115.06892</ArticleId><ArticleId IdType="pubmed">27217402</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinnie S.M.K., Fischer C., Tran K.M.H., Wang W., Mosquera F., Oudit G.Y., Vederas J.C. The Metalloprotease Neprilysin Degrades and Inactivates Apelin Peptides. Chembiochem. 2016;17:1495–1498. doi: 10.1002/cbic.201600244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.201600244</ArticleId><ArticleId IdType="pubmed">27377680</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou N., Zhang X., Fan X., Argyris E., Fang J., Acheampong E., DuBois G.C., Pomerantz R.J. The N-terminal domain of APJ, a CNS-based coreceptor for HIV-1, is essential for its receptor function and coreceptor activity. Virology. 2003;317:84–94. doi: 10.1016/j.virol.2003.08.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2003.08.026</ArticleId><ArticleId IdType="pubmed">14675627</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou M.X., Liu H.Y., Haraguchi Y., Soda Y., Tatemoto K., Hoshino H. Hoshino. Apelin peptides block the entry of human immunodeficiency virus (HIV) FEBS Lett. 2000;473:15–18. doi: 10.1016/S0014-5793(00)01487-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(00)01487-3</ArticleId><ArticleId IdType="pubmed">10802050</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou N., Fang J., Mukhtar M., Acheampong E., Pomerantz R.J. Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther. 2004;11:1703–1712. doi: 10.1038/sj.gt.3302339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gt.3302339</ArticleId><ArticleId IdType="pubmed">15306840</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y., Kuba K., Penninger J.M. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp. Physiol. 2008;93:543–548. doi: 10.1113/expphysiol.2007.040048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/expphysiol.2007.040048</ArticleId><ArticleId IdType="pmc">PMC7197898</ArticleId><ArticleId IdType="pubmed">18448662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia H. Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease. Shock. 2016;46:239–248. doi: 10.1097/SHK.0000000000000633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000633</ArticleId><ArticleId IdType="pubmed">27082314</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J., Park M.-Y., Kim Y., Jun Y., Lee U., Oh C.-M. Apelin as a new therapeutic target for COVID-19 treatment. QJM. 2023;116:197–204. doi: 10.1093/qjmed/hcac229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcac229</ArticleId><ArticleId IdType="pmc">PMC9619586</ArticleId><ArticleId IdType="pubmed">36200913</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto S., Amaya F., Oh-hashi K., Kiuchi K., Hashimoto S. Expression of neutral endopeptidase activity during clinical and experimental acute lung injury. Respir. Res. 2010;11:164. doi: 10.1186/1465-9921-11-164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1465-9921-11-164</ArticleId><ArticleId IdType="pmc">PMC3009633</ArticleId><ArticleId IdType="pubmed">21114838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellis A., Mauro C., Barbato E., Trimarco B., Morisco C. The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. Int. J. Mol. Sci. 2020;21:8612. doi: 10.3390/ijms21228612.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21228612</ArticleId><ArticleId IdType="pmc">PMC7696732</ArticleId><ArticleId IdType="pubmed">33203141</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri V.M., Rubenfeld G.D., Thompson B.T., Ferguson N.D., Caldwell E., Fan E., Camporota L., Slutsky A.S., ARDS Definition Task Force Acute respiratory distress syndrome: The Berlin Definition. JAMA. 2012;307:2526–2533.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay M.A., Arabi Y., Arroliga A.C., Bernard G., Bersten A.D., Brochard L.J., Calfee C.S., Combes A., Daniel B.M., Ferguson N.D., et al. A New Global Definition of Acute Respiratory Distress Syndrome. Am. J. Respir. Crit. Care Med. 2024;209:37–47. doi: 10.1164/rccm.202303-0558WS.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202303-0558WS</ArticleId><ArticleId IdType="pmc">PMC10870872</ArticleId><ArticleId IdType="pubmed">37487152</ArticleId></ArticleIdList></Reference><Reference><Citation>Coquerel D., Lamoureux J., Chagnon F., Trân K., Sage M., Fortin-Pellerin E., Delile E., Sainsily X., Fournier J., Dumont A.A., et al. Apelin-13 in septic shock: Effective in supporting hemodynamics in sheep but compromised by enzymatic breakdown in patients. Sci. Rep. 2021;11:22770. doi: 10.1038/s41598-021-02087-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-02087-4</ArticleId><ArticleId IdType="pmc">PMC8611018</ArticleId><ArticleId IdType="pubmed">34815457</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J., Pabon M., Choi A.M.K., Siempos I.I., Fredenburgh L.E., Baron R.M., Jeon K., Chung C.R., Yang J.H., Park C.M., et al. Plasma surfactant protein-D as a diagnostic biomarker for acute respiratory distress syndrome: Validation in US and Korean cohorts. BMC Pulm. Med. 2017;17:204. doi: 10.1186/s12890-017-0532-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-017-0532-1</ArticleId><ArticleId IdType="pmc">PMC5731189</ArticleId><ArticleId IdType="pubmed">29246207</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong M., Xiong Y., Zhu C., Xu H., Zheng Q., Jiang Y., Zou L., Xiao X., Chen F., Yan X., et al. Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity. BMC Infect. Dis. 2021;21:737. doi: 10.1186/s12879-021-06447-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06447-3</ArticleId><ArticleId IdType="pmc">PMC8329621</ArticleId><ArticleId IdType="pubmed">34344306</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvioni L., Testa F., Sulejmani A., Pepe F., Lovaglio P.G., Berta P., Dominici R., Leoni V., Prosperi D., Vittadini G., et al. Surfactant protein D (SP-D) as a biomarker of SARS-CoV-2 infection. Clin. Chim. Acta. 2022;537:140–145. doi: 10.1016/j.cca.2022.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2022.10.013</ArticleId><ArticleId IdType="pmc">PMC9617654</ArticleId><ArticleId IdType="pubmed">36341812</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisman D.E., Mehta A., Thompson B.T., Charland N.C., Gonye A.L.K., Gushterova I., Kays K.R., Khanna H.K., LaSalle T.J., Lavin-Parsons K.M., et al. Endothelial, and Organ Injury Marker Dynamics in Severe COVID-19. Am. J. Respir. Crit. Care Med. 2022;205:507–519. doi: 10.1164/rccm.202106-1514OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202106-1514OC</ArticleId><ArticleId IdType="pmc">PMC8906476</ArticleId><ArticleId IdType="pubmed">34878969</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomas D.A., Silverman E.K., Edwards L.D., Locantore N.W., Miller B.E., Horstman D.H., Tal-Singer R. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur. Respir. J. 2009;34:95–102. doi: 10.1183/09031936.00156508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00156508</ArticleId><ArticleId IdType="pubmed">19164344</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri G.U., Headley S., Kohler G., Stentz F., Tolley E., Umberger R., Leeper K. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest. 1995;107:1062–1073. doi: 10.1378/chest.107.4.1062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.107.4.1062</ArticleId><ArticleId IdType="pubmed">7705118</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J., Park D.W., Moon S., Cho H.J., Park J.H., Seok H., Choi W.S. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: A prospective controlled study according to the Sepsis-3 definitions. BMC Infect. Dis. 2019;19:968. doi: 10.1186/s12879-019-4618-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-019-4618-7</ArticleId><ArticleId IdType="pmc">PMC6852730</ArticleId><ArticleId IdType="pubmed">31718563</ArticleId></ArticleIdList></Reference><Reference><Citation>Filbin M.R., Mehta A., Schneider A.M., Kays K.R., Guess J.R., Gentili M., Fenyves B.G., Charland N.C., Gonye A.L.K., Gushterova I., et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep. Med. 2021;2:100287. doi: 10.1016/j.xcrm.2021.100287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100287</ArticleId><ArticleId IdType="pmc">PMC8091031</ArticleId><ArticleId IdType="pubmed">33969320</ArticleId></ArticleIdList></Reference><Reference><Citation>Breuniger L.M., Dempsey W.L., Uhl J., Murasko D.M. Hydrocortisone regulation of interleukin-6 protein production by a purified population of human peripheral blood monocytes. Clin. Immunol. Immunopathol. 1993;69:205–214. doi: 10.1006/clin.1993.1171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/clin.1993.1171</ArticleId><ArticleId IdType="pubmed">8403558</ArticleId></ArticleIdList></Reference><Reference><Citation>Awasthi S., Wagner T., Venkatakrishnan A.J., Puranik A., Hurchik M., Agarwal V., Conrad I., Kirkup C., Arunachalam R., O’Horo J., et al. Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients. Cell Death Discov. 2021;7:55. doi: 10.1038/s41420-021-00429-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-021-00429-9</ArticleId><ArticleId IdType="pmc">PMC7958587</ArticleId><ArticleId IdType="pubmed">33723251</ArticleId></ArticleIdList></Reference><Reference><Citation>D’Agnillo F., Walters K.A., Xiao Y., Sheng Z.M., Scherler K., Park J., Gygli S., Rosas L.A., Sadtler K., Kalish H., et al. Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19. Sci. Transl. Med. 2021;13:eabj7790. doi: 10.1126/scitranslmed.abj7790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abj7790</ArticleId><ArticleId IdType="pmc">PMC11000440</ArticleId><ArticleId IdType="pubmed">34648357</ArticleId></ArticleIdList></Reference><Reference><Citation>Salles E.L., Khodadadi H., Jarrahi A. Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome. J. Cell Mol. Med. 2020;24:12869–12872. doi: 10.1111/jcmm.15883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15883</ArticleId><ArticleId IdType="pmc">PMC7686987</ArticleId><ArticleId IdType="pubmed">33058425</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Shi Q., Tang L., Wang H., Wang D. Apelin-13 ameliorates LPS-induced endothelial-to-mesenchymal transition and post ALI pulmonary fibrosis by suppressing TGFB1 signaling. Shock. 2023;59:108–117. doi: 10.1097/SHK.0000000000002046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000002046</ArticleId><ArticleId IdType="pubmed">36377383</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian S., Zhang X., Shen Y., He S., Chen Z., Zhou L., Jiang W. Protective effect of apelin-13 on ventilator-induced acute lung injury. Mol. Biol. Rep. 2024;51:74. doi: 10.1007/s11033-023-08911-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-023-08911-6</ArticleId><ArticleId IdType="pubmed">38175266</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Zhu H., Lin L., Lu L., Chen L., Zeng L., Yue W., Kong X., Zhang H. Apelin-13 improves pulmonary epithelial barrier function in a mouse model of LPS-induced acute lung injury by inhibiting Chk1-mediated DNA damage. Biochem. Pharmacol. 2024;226:116297. doi: 10.1016/j.bcp.2024.116297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2024.116297</ArticleId><ArticleId IdType="pubmed">38801925</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q., Wang Y., Yang H., Wang J., Zhang J., Liu D. Apelin-36 protects against lipopolysaccharide-induced acute lung injury by inhibiting the ASK1/MAPK signaling pathway. Mol. Med. Rep. 2021;23:6. doi: 10.3892/mmr.2020.11644.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2020.11644</ArticleId><ArticleId IdType="pmc">PMC7673347</ArticleId><ArticleId IdType="pubmed">33179090</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang T., Chen D., Ye W., Chen W., Zhang M., Hao J., Xu L., Bai X., Mao S. Effect and mechanism of apelin on lipopolysaccharide induced acute pulmonary vascular endothelial barrier dysfunction. Sci. Rep. 2023;13:1560. doi: 10.1038/s41598-023-27889-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-27889-6</ArticleId><ArticleId IdType="pmc">PMC9883263</ArticleId><ArticleId IdType="pubmed">36707689</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostamzadeh F., Najafipour H., Yazdani R., Nakhaei S., Langari A.A. Changes in serum levels of apelin and nitric oxide in hospitalized patients with COVID-19: Association with hypertension, diabetes, obesity, and severity of disease. Eur. J. Med. Res. 2022;27:243. doi: 10.1186/s40001-022-00852-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-022-00852-3</ArticleId><ArticleId IdType="pmc">PMC9645746</ArticleId><ArticleId IdType="pubmed">36352477</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z., Liu J., Shi D., Chen W., Li J., Yan R., Bi Y., Hu W., Zhu Z., Yu Y., et al. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int. J. Biol. Sci. 2020;16:2382–2391. doi: 10.7150/ijbs.47652.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.47652</ArticleId><ArticleId IdType="pmc">PMC7378642</ArticleId><ArticleId IdType="pubmed">32760206</ArticleId></ArticleIdList></Reference><Reference><Citation>Sont J.K., van Krieken J.H., van Klink H.C., Roldaan A.C., Apap C.R., Willems L.N., Sterk P.J. Enhanced expression of neutral endopeptidase (NEP) in airway epithelium in biopsies from steroid- versus nonsteroid-treated patients with atopic asthma. Am. J. Respir. Cell Mol. Biol. 1997;16:549–556. doi: 10.1165/ajrcmb.16.5.9160837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/ajrcmb.16.5.9160837</ArticleId><ArticleId IdType="pubmed">9160837</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson A.R., Coalson J.J., Ashton J., Larumbide M., Erdös E.G. Neutral endopeptidase in serum samples from patients with adult respiratory distress syndrome. Comparison with angiotensin-converting enzyme. Am. Rev. Respir. Dis. 1985;132:1262–1267.</Citation><ArticleIdList><ArticleId IdType="pubmed">3000235</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Zhou W., Niu Y., Zhu S., Zhang Y., Li X., Yu C. Lysyl oxidase promotes renal fibrosis via accelerating collagen cross-link driving by β-arrestin/ERK/STAT3 pathway. FASEB J. 2022;36:e22427. doi: 10.1096/fj.202200573R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202200573R</ArticleId><ArticleId IdType="pmc">PMC9544652</ArticleId><ArticleId IdType="pubmed">35792886</ArticleId></ArticleIdList></Reference><Reference><Citation>López B., González A., Díez J. Circulating Biomarkers of Collagen Metabolism in Cardiac Diseases. Circulation. 2010;121:1645–1654. doi: 10.1161/CIRCULATIONAHA.109.912774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.912774</ArticleId><ArticleId IdType="pubmed">20385961</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesarwi O.A., Shin M.K., Drager L.F., Bevans-Fonti S., Jun J.C., Putcha N., Torbenson M.S., Pedrosa R.P., Lorenzi-Filho G., Steele K.E., et al. Lysyl Oxidase as a Serum Biomarker of Liver Fibrosis in Patients with Severe Obesity and Obstructive Sleep Apnea. Sleep. 2015;38:1583–1591. doi: 10.5665/sleep.5052.</Citation><ArticleIdList><ArticleId IdType="doi">10.5665/sleep.5052</ArticleId><ArticleId IdType="pmc">PMC4576332</ArticleId><ArticleId IdType="pubmed">26085300</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen X.-X., Nishimoto T., Takihara T., Mlakar L., Bradshaw A.D., Feghali-Bostwick C. Lysyl oxidase directly contributes to extracellular matrix production and fibrosis in systemic sclerosis. Am. J. Physiol. Lung Cell Mol. Physiol. 2021;320:L29–L40. doi: 10.1152/ajplung.00173.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00173.2020</ArticleId><ArticleId IdType="pmc">PMC7847064</ArticleId><ArticleId IdType="pubmed">33026236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumarasamy A., Schmitt I., Nave A.H., Reiss I., van der Horst I., Dony E., Roberts J.D., Jr., de Krijger R.R., Tibboel D., Seeger W., et al. Lysyl oxidase activity is dysregulated during impaired alveolarization of mouse and human lungs. Am. J. Respir. Crit. Care Med. 2009;180:1239–1252. doi: 10.1164/rccm.200902-0215OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200902-0215OC</ArticleId><ArticleId IdType="pmc">PMC5451144</ArticleId><ArticleId IdType="pubmed">19797161</ArticleId></ArticleIdList></Reference><Reference><Citation>Mammoto A., Mammoto T., Kanapathipillai M., Yung C.W., Jiang E., Jiang A., Lofgren K., Gee E.P., Ingber D.E. Control of lung vascular permeability and endotoxin-induced pulmonary oedema by changes in extracellular matrix mechanics. Nat. Commun. 2013;4:1759. doi: 10.1038/ncomms2774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2774</ArticleId><ArticleId IdType="pubmed">23612300</ArticleId></ArticleIdList></Reference><Reference><Citation>Beerlage C., Greb J., Kretschmer D., Assaggaf M., Trackman P.C., Hansmann M.L., Bonin M., Eble J.A., Peschel A., Brüne B., et al. Hypoxia-inducible factor 1-regulated lysyl oxidase is involved in Staphylococcus aureus abscess formation. Infect. Immun. 2013;81:2562–2573. doi: 10.1128/IAI.00302-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00302-13</ArticleId><ArticleId IdType="pmc">PMC3697610</ArticleId><ArticleId IdType="pubmed">23649089</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins D.F., Kimura K., Iwano M., Haase V.H. Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle. 2008;7:1128–1132. doi: 10.4161/cc.7.9.5804.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.7.9.5804</ArticleId><ArticleId IdType="pmc">PMC3784650</ArticleId><ArticleId IdType="pubmed">18418042</ArticleId></ArticleIdList></Reference><Reference><Citation>Peinado H., Del Carmen Iglesias-de la Cruz M., Olmeda D. A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J. 2005;24:3446–3458. doi: 10.1038/sj.emboj.7600781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7600781</ArticleId><ArticleId IdType="pmc">PMC1276164</ArticleId><ArticleId IdType="pubmed">16096638</ArticleId></ArticleIdList></Reference><Reference><Citation>Pez F., Dayan F., Durivault J., Kaniewski B., Aimond G., Le Provost G.S., Deux B., Clézardin P., Sommer P., Pouysségur J., et al. The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Res. 2011;71:1647–1657. doi: 10.1158/0008-5472.CAN-10-1516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-10-1516</ArticleId><ArticleId IdType="pubmed">21239473</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi N., Wang Y., Xia Z., Zhang J., Jia S., Jiao Y., Wang C., Wang X., Zhao J., Zhang J., et al. The regulatory role of the apelin/APJ axis in scarring: Identification of upstream and downstream mechanisms. Biochim. Biophys. Acta Mol. Basis Dis. 2024;1870:167125. doi: 10.1016/j.bbadis.2024.167125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2024.167125</ArticleId><ArticleId IdType="pubmed">38508477</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang V., Davis D.A., Yarchoan R. Identification of functional hypoxia inducible factor response elements in the human lysyl oxidase gene promoter. Biochem. Biophys. Res. Commun. 2017;490:480–485. doi: 10.1016/j.bbrc.2017.06.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2017.06.066</ArticleId><ArticleId IdType="pmc">PMC6309311</ArticleId><ArticleId IdType="pubmed">28624448</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins D.F., Kimura K., Bernhardt W.M., Shrimanker N., Akai Y., Hohenstein B.B., Saito Y., Johnson R.S., Kretzler M., Cohen C.D., et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Investig. 2007;117:3810–3820. doi: 10.1172/JCI30487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI30487</ArticleId><ArticleId IdType="pmc">PMC2082142</ArticleId><ArticleId IdType="pubmed">18037992</ArticleId></ArticleIdList></Reference><Reference><Citation>White E.S., Xia M., Murray S., Dyal R., Flaherty C.M., Flaherty K.R., Moore B.B., Cheng L., Doyle T.J., Villalba J., et al. Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias. Am. J. Respir. Crit. Care Med. 2016;194:1242–1251. doi: 10.1164/rccm.201505-0862OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201505-0862OC</ArticleId><ArticleId IdType="pmc">PMC5114439</ArticleId><ArticleId IdType="pubmed">27149370</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao C., Parimon T., Espindola M.S., Hohmann M.S., Konda B., Hogaboam C.M., Stripp B.R., Chen P. Maladaptive TGF-β Signals to the Alveolar Epithelium Drive Fibrosis after COVID-19 Infection. Am. J. Respir. Crit. Care Med. 2023;208:201–204. doi: 10.1164/rccm.202302-0264LE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202302-0264LE</ArticleId><ArticleId IdType="pmc">PMC10395488</ArticleId><ArticleId IdType="pubmed">37236627</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan J., Wang A., Cao J., Chen L. Apelin/APJ system: An emerging therapeutic target for respiratory diseases. Cell Mol. Life Sci. 2020;77:2919–2930. doi: 10.1007/s00018-020-03461-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-020-03461-7</ArticleId><ArticleId IdType="pmc">PMC11105096</ArticleId><ArticleId IdType="pubmed">32128601</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Q., Wang X., Cao Z., Xin C., Zhang J., Li S. The Apelin/APJ System: A Potential Therapeutic Target for Sepsis. J. Inflamm. Res. 2024;17:313–330. doi: 10.2147/JIR.S436169.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S436169</ArticleId><ArticleId IdType="pmc">PMC10800090</ArticleId><ArticleId IdType="pubmed">38250143</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>